Japan · Delayed Price · Currency is JPY RaQualia Pharma Statistics
Total Valuation
RaQualia Pharma has a market cap or net worth of JPY 14.97 billion. The enterprise value is 12.96 billion.
| Market Cap | 14.97B |
| Enterprise Value | 12.96B |
Important Dates
The last earnings date was Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RaQualia Pharma has 26.03 million shares outstanding. The number of shares has increased by 14.40% in one year.
| Current Share Class | 26.03M |
| Shares Outstanding | 26.03M |
| Shares Change (YoY) | +14.40% |
| Shares Change (QoQ) | +1.95% |
| Owned by Insiders (%) | 12.51% |
| Owned by Institutions (%) | -3.74% |
| Float | 17.41M |
Valuation Ratios
The trailing PE ratio is 90.90.
| PE Ratio | 90.90 |
| Forward PE | n/a |
| PS Ratio | 3.84 |
| PB Ratio | 1.91 |
| P/TBV Ratio | 3.53 |
| P/FCF Ratio | 32.47 |
| P/OCF Ratio | 29.88 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.98, with an EV/FCF ratio of 28.10.
| EV / Earnings | 80.47 |
| EV / Sales | 3.32 |
| EV / EBITDA | 15.98 |
| EV / EBIT | 38.67 |
| EV / FCF | 28.10 |
Financial Position
The company has a current ratio of 5.78, with a Debt / Equity ratio of 0.34.
| Current Ratio | 5.78 |
| Quick Ratio | 5.18 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 3.31 |
| Debt / FCF | 5.82 |
| Interest Coverage | 5.58 |
Financial Efficiency
Return on equity (ROE) is 2.28% and return on invested capital (ROIC) is 2.20%.
| Return on Equity (ROE) | 2.28% |
| Return on Assets (ROA) | 2.00% |
| Return on Invested Capital (ROIC) | 2.20% |
| Return on Capital Employed (ROCE) | 3.37% |
| Weighted Average Cost of Capital (WACC) | 7.90% |
| Revenue Per Employee | 45.87M |
| Profits Per Employee | 1.89M |
| Employee Count | 85 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 3.96 |
Taxes
In the past 12 months, RaQualia Pharma has paid 241.00 million in taxes.
| Income Tax | 241.00M |
| Effective Tax Rate | 59.95% |
Stock Price Statistics
The stock price has increased by +5.89% in the last 52 weeks. The beta is 0.89, so RaQualia Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +5.89% |
| 50-Day Moving Average | 494.26 |
| 200-Day Moving Average | 762.06 |
| Relative Strength Index (RSI) | 68.02 |
| Average Volume (20 Days) | 160,395 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RaQualia Pharma had revenue of JPY 3.90 billion and earned 161.00 million in profits. Earnings per share was 6.33.
| Revenue | 3.90B |
| Gross Profit | 3.24B |
| Operating Income | 335.00M |
| Pretax Income | 402.00M |
| Net Income | 161.00M |
| EBITDA | 811.00M |
| EBIT | 335.00M |
| Earnings Per Share (EPS) | 6.33 |
Balance Sheet
The company has 4.70 billion in cash and 2.68 billion in debt, with a net cash position of 2.01 billion or 77.29 per share.
| Cash & Cash Equivalents | 4.70B |
| Total Debt | 2.68B |
| Net Cash | 2.01B |
| Net Cash Per Share | 77.29 |
| Equity (Book Value) | 7.83B |
| Book Value Per Share | 300.83 |
| Working Capital | 5.12B |
Cash Flow
In the last 12 months, operating cash flow was 501.00 million and capital expenditures -40.00 million, giving a free cash flow of 461.00 million.
| Operating Cash Flow | 501.00M |
| Capital Expenditures | -40.00M |
| Depreciation & Amortization | 476.00M |
| Net Borrowing | -512.00M |
| Free Cash Flow | 461.00M |
| FCF Per Share | 17.71 |
Margins
Gross margin is 83.00%, with operating and profit margins of 8.59% and 4.13%.
| Gross Margin | 83.00% |
| Operating Margin | 8.59% |
| Pretax Margin | 10.31% |
| Profit Margin | 4.13% |
| EBITDA Margin | 20.80% |
| EBIT Margin | 8.59% |
| FCF Margin | 11.82% |
Dividends & Yields
RaQualia Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.40% |
| Shareholder Yield | -14.40% |
| Earnings Yield | 1.08% |
| FCF Yield | 3.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RaQualia Pharma has an Altman Z-Score of 4.47 and a Piotroski F-Score of 8.
| Altman Z-Score | 4.47 |
| Piotroski F-Score | 8 |